NCT00014560 is a Phase 1 clinical trial of bispecific antibody 4G7xH22 in Leukemia, sponsored by Dartmouth-Hitchcock Medical Center.

Who is sponsoring NCT00014560?

NCT00014560 is sponsored by Dartmouth-Hitchcock Medical Center.

What drugs are being tested in NCT00014560?

Interventions in NCT00014560: bispecific antibody 4G7xH22, sargramostim.

What condition does NCT00014560 study?

NCT00014560 studies Leukemia, Lymphoma.

Is NCT00014560 still recruiting?

NCT00014560 is currently terminated. Last updated 3 May 2018.

Are results published for NCT00014560?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-05-03 · How we verify

NCT00014560

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Terminated Phase 1 Results posted Last updated 3 May 2018

What this trial tests

Phase 1 trial testing bispecific antibody 4G7xH22 in Leukemia in 3 participants. Terminated before completion.

Timeline

28 September 2000

Primary endpoint
14 February 2003

14 February 2003

Quick facts

Lead sponsor	Dartmouth-Hitchcock Medical Center
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	28 September 2000
Primary completion	14 February 2003
Estimated completion	14 February 2003
Sites	1 location across United States

Drugs / interventions tested

bispecific antibody 4G7xH22 — full drug profile →
sargramostim (SARGRAMOSTIM) — full drug profile →

Conditions studied

Leukemia — all drugs for Leukemia →
Lymphoma — all drugs for Lymphoma →

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

Adults 18 to 120, any sex, with Leukemia or Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of antibody therapy in treating patients who have refractory or relapsed non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Bispecific antibodies: design, therapy, perspectives.
Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. · · 2018 · cited 210× · PMID 29403265 · DOI 10.2147/dddt.s151282
Bispecific antibodies and their applications.
Fan G, Wang Z, Hao M, Li J. · · 2015 · cited 200× · PMID 26692321 · DOI 10.1186/s13045-015-0227-0
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
Guo X, Wu Y, Xue Y, Xie N, et al · · 2023 · cited 15× · PMID 38106416 · DOI 10.3389/fimmu.2023.1291836
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P, Nikkarinen A, Ek S, Glimelius I. · · 2024 · cited 5× · PMID 38566987 · DOI 10.3389/fimmu.2024.1373269

Verify or expand the search:

Other recruiting trials for Leukemia

Currently open trials in the same condition.

NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting

Other Dartmouth-Hitchcock Medical Center trials

Trials by the same sponsor.

NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00014560 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
Last refreshed: 3 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00014560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing